# US 11,998,536 B2 · Decreasing expression level of proteasome subunit genes by treating a human subject with a nitroxide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,536 B2
- Document ID: US11998536B2
- Status: Granted
- Kind: B2
- Application number: 17/074,228
- Filed: 2020-10-19
- Published: 2021-06-10
- Granted: 2024-06-04
- Earliest claimed: 2018-01-22
- Applicants: Louis Habash
- Inventors: Louis Habash
- Web page: https://patentgrep.com/patent/US11998536B2

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Some embodiments disclosed herein include a method for decreasing gene expression of a gene. The methods can include identifying a human subject over the age of 35 and having an increase expression level of a gene associated with proteasome activity; and administering to the human subject an effective amount of a nitroxide antioxidant, whereby expression level of the gene is decreased.

## Claims

### Claim 1

A method for decreasing the expression level of Psma6 in a human subject, the method comprising:
identifying the human subject both having an increased expression level of Psma6 and having a disease associated with the increased expression level Psma6; and
administering an effective amount of a nitroxide antioxidant to the human subject,
the nitroxide antioxidant selected from the group consisting of 2-ethyl-2,5,5-trimethyl-3-oxazolidine-1-oxyl (OXANO), 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO), 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), 4-amino-2,2,6,6-tetramethyl-1-piperidinyloxy (Tempamine), 3-Aminomethyl-PROXYL, 3-Cyano-PROXYL, 3-Carbamoyl-PROXYL, 3-Carboxy-PROXYL, and 4-Oxo-TEMPO,
whereby the expression level of Psma6 is decreased,
wherein the disease associated with the increased expression level of Psma6 is atherosclerosis, and
wherein identifying the human subject having an increased expression level of Psma6 comprises measuring the expression level of Psma6 in the human subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is TEMPOL.

### Claim 3 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is OXANO.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is TEMPO.

### Claim 5 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is Tempamine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is 3-Aminomethyl-PROXYL.

### Claim 7 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is 3-Cyano-PROXYL.

### Claim 8 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is 3-Carbamoyl-PROXYL.

### Claim 9 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is 3-Carboxy-PROXYL.

### Claim 10 (depends on 1)

The method of claim 1, wherein the nitroxide antioxidant is 4-Oxo-TEMPO.